How a startup named after a biblical balm became a pharmaceutical titan
In short: Founded in 1987 as a small biotech venture, Gilead Sciences evolved from a struggling startup into a global pharmaceutical powerhouse. While its innovations in antiviral treatments for HIV and hepatitis have reshaped medicine, the company has also faced intense scrutiny over its pricing strategies and aggressive acquisition-led growth model.
Gilead Sciences began in June 1987 as Oligogen, a project conceived by medical doctor Michael L. Riordan. Inspired by the "Balm of Gilead" and the discovery of aspirin-like compounds in willow trees, Riordan sought to develop antisense therapy using small strands of DNA. The company faced a precarious start, with Riordan later describing the first decade as a stressful period where the firm narrowly avoided collapse multiple times. It debuted on the NASDAQ in 1992, raising $86.25 million, and eventually moved its headquarters to Foster City, California, in 1988.
The company’s trajectory shifted significantly in the 2000s as it transitioned from a biotech startup to a large-scale pharmaceutical entity. This evolution was driven by a series of strategic acquisitions, such as the 1999 purchase of NeXstar Pharmaceuticals, which provided the sales infrastructure Gilead lacked. Later, the $10.4 billion acquisition of Pharmasset in 2011 solidified its dominance in hepatitis C treatment. By 2017, the company entered the cell therapy market by acquiring Kite Pharma for $11.9 billion, further diversifying its portfolio beyond its core antiviral focus.
Despite its scientific achievements, Gilead’s business practices have drawn significant criticism. Observers have frequently highlighted the high pricing of drugs like Sovaldi and Truvada in the United States compared to production costs and prices in developing nations. The company has also navigated complex political ties; notably, Donald Rumsfeld served as chairman from 1997 to 2001, and his significant holdings in the company saw major gains during the 2004 avian flu pandemic. Today, Gilead remains a massive player in the industry, continuing to expand its reach through both internal research and ongoing corporate acquisitions.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Gilead Sciences
- Also: find-and-update.company-information.service.gov.uk — GILEAD SCIENCES LTD overview - Find and update company information - GOV.UK
To cite this card, link to https://intellectplus.co.uk/app/culture-gilead-sciences.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in US culture · More in Cultures · Latest · A–Z · All topics
